Summary
The current treatment landscape for underactive bladder largely depends on pharmacological management and catheterization.
Despite the significant unmet need, the clinical development pipeline for UAB remains relatively sparse.
Notable candidates include TAC-302, being developed by Taiho Pharmaceutical and ZG-802 from Zeria Pharmaceutical, both currently in Phase II development, along with SFG-02 from SFG Sciences, which is in Phase I clinical evaluation. These emerging therapies highlight ongoing efforts to address the limited treatment options available for UAB.
Underactive bladder syndrome traps millions in a silent struggle with incomplete b...
